Добірка наукової літератури з теми "Medication overuse headache"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Medication overuse headache".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Medication overuse headache"
1
Scher, Ann I., Paul B. Rizzoli, and Elizabeth W. Loder. "Medication overuse headache." Neurology 89, no. 12 (August 18, 2017): 1296–304. http://dx.doi.org/10.1212/wnl.0000000000004371.
Повний текст джерелаАнотація:
It is a widely accepted idea that medications taken to relieve acute headache pain can paradoxically worsen headache if used too often. This type of secondary headache is referred to as medication overuse headache (MOH); previously used terms include rebound headache and drug-induced headache. In the absence of consensus about the duration of use, amount, and type of medication needed to cause MOH, the default position is conservative. A common recommendation is to limit treatment to no more than 10 or 15 days per month (depending on medication type) to prevent headache frequency progression. Medication withdrawal is often recommended as a first step in treatment of patients with very frequent headaches. Existing evidence, however, does not provide a strong basis for such causal claims about the relationship between medication use and frequent headache. Observational studies linking treatment patterns with headache frequency are by their nature confounded by indication. Medication withdrawal studies have mostly been uncontrolled and often have high dropout rates. Evaluation of this evidence suggests that only a minority of patients required to limit the use of symptomatic medication may benefit from treatment limitation. Similarly, only a minority of patients deemed to be overusing medications may benefit from withdrawal. These findings raise serious questions about the value of withholding or withdrawing symptom-relieving medications from people with frequent headaches solely to prevent or treat MOH. The benefits of doing so are smaller, and the harms larger, than currently recognized. The concept of MOH should be viewed with more skepticism. Until the evidence is better, we should avoid dogmatism about the use of symptomatic medication. Frequent use of symptom-relieving headache medications should be viewed more neutrally, as an indicator of poorly controlled headaches, and not invariably a cause.
2
Beckmann, Yesim, Sevgin Gökçe, Nabi Zorlu, H. Sabiha Türe, and Fazıl Gelal. "Longitudinal assessment of gray matter volumes and white matter integrity in patients with medication-overuse headache." Neuroradiology Journal 31, no. 2 (January 31, 2018): 150–56. http://dx.doi.org/10.1177/1971400918756374.
Повний текст джерелаАнотація:
Background Medication-overuse headache is a common clinical entity, but neuroimaging studies investigating volumetric and microstructural alterations of the brain in medication-overuse headache are rare. Therefore, in the current longitidunal study we evaluated gray matter volume and white matter integrity in patients with medication-overuse headache before and after drug withdrawal. Methods A prospective study evaluated 27 patients with medication-overuse headache and 27 age-, sex-, and education-matched healthy adults. High-resolution T1-weighted magnetic resonance imaging and diffusion tensor imaging were obtained from the control group and medication-overuse headache patients before and six months after drug withdrawal. Tract-based spatial statistics of multiple diffusivity indices and voxel-based morphometry were employed to investigate white and gray matter abnormalities. Results No correlation was found between age, gender, education and smoking status in both groups. The most commonly overused medications were simple analgesics (96.3%) and combined analgesics (3.7%). The mean duration of the history of medication overuse and headaches was 56.7 ± 63.5 months. White matter diffusional and gray matter morphological alterations including volume, fractional anisotropy, radial diffusivity, and axial diffusivity analyses showed no significant relationship in the patients before and six months after withdrawal of analgesics. Also no difference was observed between the patients versus controls. Conclusion Our data demonstrated no structural alterations within the brain in medication-overuse headache.
3
Park, Hong-Kyun, and Soo-Jin Cho. "Comprehensive approach for the treatment of medication-overuse headache." Journal of the Korean Medical Association 64, no. 12 (December 10, 2021): 843–51. http://dx.doi.org/10.5124/jkma.2021.64.12.843.
Повний текст джерелаАнотація:
Background: Medication-overuse headache (MOH) is defined by the International Classification of Headache Disorders as a headache in patients with a pre-existing primary headache disorder that occurs on 15 or more days per month for more than 3 months. It is caused by overuse of medication for acute or symptomatic headache treatment. Regular and frequent use of acute or symptomatic medications can worsen headaches and lead to chronic headache or MOH. MOH is a burdensome medical condition that is difficult to treat, and the frequent recurrence of headaches may result in disability in individuals and impair socioeconomic outcomes.Current Concepts: Awareness of MOH and the education of patients, the general population, and healthcare providers are important for the first step of treatment. Scientific research regarding the treatment of MOH has been published in the past few years.Discussion and Conclusion: Physicians should educate and counsel patients to stop or at least reduce the intake of acute or symptomatic medications that can be discontinued abruptly or tapered slowly. During the period after the discontinuation of the overused medications, some withdrawal symptoms including headache might be manageable with bridging therapy. Evidence-based preventive therapies including anticonvulsants (topiramate and divalproex sodium), botulinum toxin A, and medications acting by antagonism of the calcitonin generelated peptide pathway might be helpful in patients with MOH for both avoiding the overused medication and preventing the relapse of overuse. A comprehensive and multidisciplinary approach may improve the outcomes of patients with MOH.
4
Chiang, Chia-Chun, Todd J. Schwedt, Shuu-Jiun Wang, and David W. Dodick. "Treatment of medication-overuse headache: A systematic review." Cephalalgia 36, no. 4 (June 29, 2015): 371–86. http://dx.doi.org/10.1177/0333102415593088.
Повний текст джерелаАнотація:
Introduction The objective of this review is to provide an evidence-based discussion of different treatment strategies for medication-overuse headache (MOH). Method We searched PubMed for articles discussing the treatment and prognosis of MOH published between 2004 and August 2014. Titles, abstract and articles were reviewed systematically. The level of evidence provided by each study of the included articles was determined according to the American Academy of Neurology Clinical practice guideline manual. We discuss the level of evidence to support the early discontinuation/withdrawal of overused medications, the level of evidence to support the use of preventive treatment, the short- and long-term prognosis, and the outcome according to the class of drug overused in patients diagnosed with MOH. Results The initial search resulted in 1313 articles; 68 articles met our inclusion criteria and were discussed. The level of evidence to support early discontinuation of overused medications alone is low due to the absence of controlled studies. Adding preventive medication to early discontinuation led to a better outcome than early discontinuation alone. For patients with chronic migraine (CM) and medication overuse (MO), there are large randomized control trials supporting the use of onabotulinumtoxinA and topiramate without early discontinuation of overuse; however, the evidence is limited since data were obtained from post hoc analysis. Conclusion Considering current available evidence and the systemic toxicity of overusing acute headache medication, we suggest discontinuation of the overused medication with the addition of preventive medication. Appropriately sized, randomized controlled trials evaluating the safety and long-term efficacy of preventive medication plus early discontinuation of overuse vs preventive medication alone vs early discontinuation of overuse alone are needed.
5
Schwedt, Todd J., Joseph G. Hentz, Soma Sahai-Srivastava, Natalia Murinova, Nicole M. Spare, Christina Treppendahl, Vincent T. Martin, et al. "Patient-Centered Treatment of Chronic Migraine With Medication Overuse." Neurology 98, no. 14 (February 15, 2022): e1409-e1421. http://dx.doi.org/10.1212/wnl.0000000000200117.
Повний текст джерелаАнотація:
Background and ObjectivesOveruse of symptomatic (i.e., acute) medications is common among those with chronic migraine. It is associated with developing frequent headaches, medication side effects, and reduced quality of life. The optimal treatment strategy for patients who have chronic migraine with medication overuse (CMMO) has long been debated. The study objective was to determine whether migraine preventive therapy without switching or limiting the frequency of the overused medication was noninferior to migraine preventive therapy with switching from the overused medication to an alternative medication that could be used on ≤2 d/wk.MethodsThe Medication Overuse Treatment Strategy (MOTS) trial was an open-label, pragmatic clinical trial, randomizing adult participants 1:1 to migraine preventive medication and (1) switching from the overused medication to an alternative used ≤2 d/wk or (2) continuation of the overused medication with no maximum limit. Participants were enrolled between February 2017 and December 2020 from 34 clinics in the United States, including headache specialty, general neurology, and primary care clinics. The primary outcome was moderate to severe headache day frequency during weeks 9 to 12 and subsequently during weeks 1 to 2 after randomization.ResultsSeven hundred twenty participants were randomized; average age was 44 (SD 13) years; and 87.5% were female. At baseline, participants averaged 22.5 (SD 5.1) headache days over 4 weeks, including 12.8 (SD 6.7) moderate to severe headache days and 21.4 (SD 5.8) days of symptomatic medication use. Migraine preventive medication without switching of the overused medication was not inferior to preventive medication with switching for moderate to severe headache day frequency during weeks 9 to 12 (switching 9.3 [SD 7.2] vs no switching 9.1 [SD 6.8]; p = 0.75, 95% CI −1.0 to 1.3). The treatment strategies also provided similar outcomes during the first 2 weeks (switching 6.6 [SD 3.7] moderate to severe headaches days vs no switching 6.4 [SD 3.6]; p = 0.57, 95% CI −0.4 to 0.7).DiscussionWhen reduction in moderate to severe headache days was used as the outcome of interest for the management of CMMO, migraine preventive medication without switching or limiting symptomatic medication is not inferior to migraine preventive medication with switching to a different symptomatic medication with a maximum limit of 2 treatment days per week.Trial Registration InformationClinicalTrials.gov identifier NCT02764320.Classification of EvidenceThis study provides Class III evidence that, for patients who have CMMO, migraine preventive medication without switching or limiting the overused medication is noninferior to migraine preventive medication with switching and limiting symptomatic medication.
6
Schwedt, Todd J., Dawn C. Buse, Charles E. Argoff, Michael L. Reed, Kristina M. Fanning, Cory R. Hussar, Aubrey Manack Adams, and Richard B. Lipton. "Medication Overuse and Headache Burden." Neurology: Clinical Practice 11, no. 3 (January 25, 2021): 216–26. http://dx.doi.org/10.1212/cpj.0000000000001037.
Повний текст джерелаАнотація:
ObjectiveTo estimate the relative frequency of acute medication overuse (AMO) among people with episodic migraine and chronic migraine, to characterize the types of acute medications overused for migraine, and to identify factors associated with AMO.MethodsWe analyzed data from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study (ClinicalTrials.gov, NCT01648530), a cross-sectional and longitudinal internet study that included a systematic sampling of the US population. From September 2012 to November 2013, the CaMEO Study respondents participated in different modules to collect data on the clinical course of migraine, family burden, barriers to care, endophenotypes, and comorbidities. Among people who met the criteria for migraine consistent with the International Classification of Headache Disorders, third edition (ICHD-3), we evaluated types and frequency of medications used for headache/migraine, selected comorbidities, and emergency department (ED) and urgent care (UC) use. AMO was defined by days per month of medication use as specified by ICHD-3 criteria for medication overuse headache (MOH) without the requirement for ≥15 monthly headache days (MHDs). Nested, multivariable binary logistic regression modeling was used to identify factors associated with an increased risk of AMO.ResultsOf 16,789 CaMEO respondents with migraine, 2,975 (17.7%) met the AMO criteria. Approximately 67.9% (2,021/2,975) of AMO respondents reported <15 MHDs. Simple analgesics, combination analgesics, and opioids were the medication classes most commonly overused. Factors associated with AMO in the final multivariable logistic regression model included ≥15 MHDs, moderate to severe disability, severe migraine interictal burden, use of preventive medication, and an ED/UC visit for headache within 6 months.ConclusionsApproximately two-thirds of respondents with AMO reported <15 MHDs and therefore did not meet the criteria for MOH. Those with AMO had greater disease burden and increased ED/UC utilization relative to people with migraine but not AMO.
7
Rahman, A., R. Habib, NB Bhowmik, and A. Haque. "Medication Overuse Headache: A Trap for the Headache Patients." BIRDEM Medical Journal 3, no. 2 (December 1, 2013): 94–98. http://dx.doi.org/10.3329/birdem.v3i2.17213.
Повний текст джерелаАнотація:
Medication Overuse Headache (MOH) was previously termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. It is not a primary headache but frequently coexists with primary chronic daily headache. All acute symptomatic medications used to treat headaches have the potential for causing MOH. Highest with opioids, butalbital-containing combination analgesics, and aspirin/ acetaminophen/caffeine combinations. The development is typically preceded by an episodic headache disorder, usually migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications. The diagnosis is based upon clinical impression. A history of analgesic use averaging more than two to three days per week in association with chronic daily headache is suggestive. The diagnosis is made when the pattern of frequent headaches fulfills the diagnostic criteria for MOH. The basic steps in the management: Patient education, withdrawal of the offending medication, bridge (transitional) therapy, establishment of a headache treatment regimen covering acute and preventive care, follow up and relapse prevention. Birdem Med J 2013; 3(2): 94-98 DOI: http://dx.doi.org/10.3329/birdem.v3i2.17213
8
Carlsen, Louise Ninett, Maria Lurenda Westergaard, Mette Bisgaard, Julie Brogaard Schytz, and Rigmor Højland Jensen. "National awareness campaign to prevent medication-overuse headache in Denmark." Cephalalgia 38, no. 7 (October 10, 2017): 1316–25. http://dx.doi.org/10.1177/0333102417736898.
Повний текст джерелаАнотація:
Background Medication-overuse headache is prevalent, but in principle preventable. Objective To describe the Danish national awareness campaign for medication-overuse headache. Methods The Danish Headache Center, the Association of Danish Pharmacies, and headache patient organizations implemented a four-month medication-overuse headache awareness campaign in 2016. Target groups were the general public, general practitioners, and pharmacists. Key messages were: Overuse of pain-medication can worsen headaches; pain-medication should be used rationally; and medication-overuse headache is treatable. A range of communication technologies was used. A survey on the public’s awareness of medication-overuse headache was conducted. Results The Danish adult population is 4.2 million. Online videos were viewed 297,000 times in three weeks. All 400 pharmacies received campaign materials. Over 28,000 leaflets were distributed. Two radio interviews were conducted. A television broadcast about headache reached an audience of 520,000. Forty articles were published in print media. Information was accessible at 32 reputable websites and five online news agencies. Three scientific papers were published. Information was available at an annual conference of general practitioners, including a headache lecture. The survey showed an increase in percentage of the public who knew about medication-overuse headache (from 31% to 38%). Conclusion A concerted campaign to prevent medication-overuse headache can be implemented through involvement of key stakeholders.
9
Wakerley, Benjamin R. "Medication-overuse headache." Practical Neurology 19, no. 5 (July 4, 2019): 399–403. http://dx.doi.org/10.1136/practneurol-2018-002048.
Повний текст джерелаАнотація:
Medication-overuse headache is defined as headache occurring on more than 15days in a month in people with pre-existing primary headache, and developing as a consequence of regular overuse of acute headache treatments. Medication-overuse headache is common in general neurology clinics and can be difficult to manage. Most patients have a background of migraine, which has slowly transformed over months and years from the episodic to chronic form; with this comes an increased use of acute migraine treatment. This paper identifies who is at risk of developing medication-overuse headache, and reviews preventive measures and current treatment strategies.
10
Bigal, ME, AM Rapoport, FD Sheftell, SJ Tepper, and RB Lipton. "Transformed Migraine and Medication Overuse in a Tertiary Headache Centre — Clinical Characteristics and Treatment Outcomes." Cephalalgia 24, no. 6 (June 2004): 483–90. http://dx.doi.org/10.1111/j.1468-2982.2004.00691.x.
Повний текст джерелаАнотація:
Studies suggest that a substantial proportion of headache sufferers presenting to headache clinics may overuse acute medications. In some cases, overuse may be responsible for the development or maintenance of a chronic daily headache (CDH) syndrome. The objectives of this study are to evaluate patterns of analgesic overuse in patients consulting a headache centre and to compare the outcomes in a group of patients who discontinued medication overuse to those of a group who continued the overuse, in patients with similar age, sex and psychological profile. We reviewed charts of 456 patients with transformed migraine (TM) and acute medication overuse defined by one of the following criteria: 1. Simple analgesic use (> 1000 mg ASA/acetaminophen) > 5 days/week; 2. Combination analgesics use (caffeine and/or butalbital) > 3 tablets a day for > 3 days a week; 3. Opiate use > 1 tablet a day for > 2 days a week; 4. Ergotamine tartrate use: 1 mg PO or 0.5 mg PR for > 2 days a week. For triptans, we empirically considered overuse > 1 tablet per day for > 5 days per week. Patients who were able to undergo detoxification and did not overuse medication (based on the above definition) after one year of follow-up were considered to have successful detoxification (Group 1). Patients who were not able to discontinue offending agents, or returned to a pattern of medication overuse within one year were considered to have unsuccessful detoxification (Group 2). We compared the following outcomes after one year of follow-up: Number of days with headache per month; Intensity of headache; Duration of headache; Headache score (frequency x intensity). The majority of patients overused more than one type of medication. Numbers of tablets taken ranged from 1 to 30 each day (mean of 5.2). Forty-eight (10.5%) subjects took > 10 tablets per day. Considering patients seen in the last 5 years, we found the following overused substances: Butalbital containing combination products, 48%; Acetaminophen, 46.2%; Opioids, 33.3%; ASA, 32.0%; Ergotamine tartrate, 11.8%; Sumatriptan, 10.7%; Nonsteroidal anti-inflammatory medications other than ASA, 9.8%; Zolmitriptan, 4.6%; Rizatriptan, 1.9%; Naratriptan, 0.6%. Total of all triptans, 17.8%. Of 456 patients, 318 (69.7%) were successfully detoxified (Group 1), and 138 (30.3%) were not (Group 2). The comparison between groups 1 and 2 after one year of follow-up showed a decrease in the frequency of headache of 73.7% in group 1 and only 17.2% in group 2 ( P < 0.0001). Similarly, the duration of head pain was reduced by 61.2% in group 1 and 14.8% in group 2 ( P < 0.0001). The headache score after one year was 18.8 in group 1 and 54 in group 2 ( P < 0.0001). A total of 225 (70.7%) successfully detoxified subjects in Group 1 returned to an episodic pattern of migraine, compared to 21 (15.3%) in Group 2 ( P < 0.001). More rigorous prescribing guidelines for patients with frequent headaches are urgently needed. Successful detoxification is necessary to ensure improvement in the headache status when treating patients who overuse acute medications.
Дисертації з теми "Medication overuse headache"
1
Matti, Salam. "Behandlas analgetikainducerad huvudvärk bäst medavbrytande av analgetikabehandling?" Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409727.
Повний текст джерелаАнотація:
Introduktion: Överanvändning av all analgetika både som monoterapi eller i kombination är ofta associerad med utveckling av en sekundär huvudvärk även kallad läkemedelsinducerad huvudvärk(MOH). Huvudvärk i sig kan behandlas på egenhand och smärtstillande läkemedel köps receptfritt. Analgetikaanvändning, missbruk och överanvändning representerar större hälsoproblem förknippade med flera negativa hälsokonsekvenser som läkemedelsinducerad huvudvärk, högre blodtryck och hjärt- och kärlsjukdomar. MOH definieras som en kronisk huvudvärksstörning vilket innebär en huvudvärk som förekommer under mer än 15 dagar per månad under mer än tre månader i sträck i kombination med en överanvändning av analgetika definierat som analgetikaintag under mer än 15 dagar i månaden under minst tre månader Metod: En systematisk litteratursökning utfördes i databaserna PubMed och CINAHL. Relevanta studietyper var randomiserade studier, systematiska översikter och kohortstudier. Studierna relevans- och kvalitetsgranskades med hjälp av granskningsmallar från Statens beredning för medicinsk och social utvärdering. Syfte: Syftet med projektet var att undersöka vilka evidens det finns för behandling av MOH med hjälp av olika tilläggsbehandlingar jämfört med att bara sätta ut analgetikan. Resultat: 10 studier inkluderades i projektet. Det framkom att tilläggsbehandlingar med prednisolon, celecoxib, botulinumtoxin och paracetamol inte ger stora fördelar jämfört med att sätta ut det överanvända läkemedlet. Tilläggsbehandlingar gav främst en minskning av biverkningar vid MOH när man sätter ut analgetikan. Istället var utbildning av patienter och motivering en stor bidragande faktor till att få patienter att avsluta sin överanvändning och därmed bota sin MOH. Utbildning gjorde att patienter minskade sina huvudvärksdagar per månad samt antal medicinerings dagar per månad utan att få tilläggsbehandling. Slutsats:Slutsatsen som kan dras av studien är att de tilläggsbehandlingar som har provats under dessa studier inte ger en tydlig förbättring av MOH utan bara symtom lindring och att enbart få patienten att förstå sjukdomen kan vara det sättet man bör gå tillväga för att bota MOH.
2
Johnson, Jacinta Lee. "Codeine, heightened pain sensitivity and medication overuse headache: a neuroimmune hypothesis and novel treatment strategy." Thesis, 2015. http://hdl.handle.net/2440/96831.
Повний текст джерелаАнотація:
Codeine is the most widely consumed opioid analgesic worldwide. It relies upon partial metabolism to morphine to elicit analgesic effects. Paradoxically, the pain-reliever morphine has previously been linked to states of increased pain sensitivity; such as medication overuse headache and opioid-induced hyperalgesia and allodynia. Despite the clinical impact of medication overuse headache the pathophysiology behind this disorder remains unclear and mechanism-based treatments are lacking. Although most acute headache treatments are alleged to cause medication overuse headache, within this thesis we conclude from the literature opioids are the drug class most strongly associated with worsening headache. In opioid-induced hyperalgesia and allodynia sensitivity to normally noxious, and non-noxious stimuli respectively, are enhanced due to opioid exposure.
Chronic morphine may exacerbate pain in the long-term by non-specifically activating toll-like receptor-4 (TLR4) on glial cells, resulting in a pro-inflammatory state that manifests clinically as increased pain. Here we hypothesise medication overuse headache is a specific form of opioid-induced hyperalgesia, which derives from a cumulative interaction between central sensitisation and glial priming, due to repeated activation of nociceptive pathways by recurrent headaches, and pain facilitation due to glial activation and subsequent neuroinflammation. The first part of this thesis examines the efficacy of a glial-attenuating treatment, ibudilast, in the clinical management of medication overuse headache induced by opioid use in a double-blind, randomised, placebo-controlled parallel group study. Patients received ibudilast 40 mg twice daily or placebo for I weeks and recorded headache and analgesic intake using a headache diary for 4-weeks prior to randomisation and throughout the treatment phase. No reduction in headache burden, opioid analgesic intake or headache related quality of life were observed in the ibudilast group compared to placebo, however, valuable safety data were obtained demonstrating ibudilast 80 mg/day is well tolerated, facilitating the use of similarly high doses in future studies for alternative indications. Prior to this PhD project the relationship between codeine and increased pain sensitivity had not been investigated. ln silico docking simulations performed as part of this PhD suggest codeine binds to MD2, an accessory protein forTLR4, signifying it may be able to induce hyperalgesia independent of conversion to morphine. Evidence that codeine can induce hyperalgesia would sit in line with our glial hypothesis for opioid overuse headache. Thus, the second part of this PhD includes a series of preclinical experiments to 1.) determine if chronic codeine alters pain sensitivity 2) ascertain if pre-existing glial activation primes for opioid-induced hyperalgesia, 3) investigate signalling pathways involved and 4) assess potential interventions to reverse exacerbated pain sensitivity. Hyperalgesia and allodynia were measured using hot plate and von Frey tests respectively, at baseline, day 3 and day 5 in mice receiving intraperitoneal codeine 2t mg/kg, morphine 20 mg/kg or saline, twice daily. Our preclinical studies demonstrate that despite providing lesser acute analgesia, equimolar codeine and morphine induced similar hot plate hyperalgesia, suggesting codeine does not rely upon conversion to morphine to increase pain sensitivity, emphasising the non-opioid receptor-dependent nature of this phenomenon. lL-RA reversed codeine-induced hyperalgesia and allodynia, and knock-out of TLR4 protected against codeine-induced pain sensitivity changes. Glial attenuation with ibudilast reversed codeine-induced allodynia and thus could be investigated as potential treatment for conditions involving codeine-induced pain enhancement.Thesis (Ph.D.) -- University of Adelaide, School of Medical Sciences, 2015
Книги з теми "Medication overuse headache"
1
Nageshwaran, Sathiji, Heather C. Wilson, Anthony Dickenson, and David Ledingham. Headache. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199664368.003.0001.
Повний текст джерелаАнотація:
This chapter on headache discusses the classification, clinical features, treatment regimes, and evidence for treatment of primary (including migraine, tension-type headache, and trigeminal autonomic cephalalgias) and secondary headache (idiopathic intracranial hypertension and medication overuse headache) disorders.
Частини книг з теми "Medication overuse headache"
1
Rizzoli, Paul. "Medication Overuse Headache." In Pain Medicine, 531–32. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43133-8_141.
Повний текст джерела
2
Mitsikostas, Dimos D., and Mohammed Al Jumah. "Medication Overuse and Headache." In Handbook of Headache, 637–50. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1700-9_50.
Повний текст джерела
3
Katsarava, Zaza. "Medication-Overuse Headache (MOH)." In Pharmacological Management of Headaches, 207–22. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-19911-5_19.
Повний текст джерела
4
Diener, Hans-Christoph, Dagny Holle-Lee, and Frederick G. Freitag. "Medication Overuse in Chronic Daily Headache." In Chronic Headache, 195–206. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-91491-6_14.
Повний текст джерела
5
Evers, S., and R. Jensen. "Treatment of Medication Overuse Headache." In European Handbook of Neurological Management, 337–44. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444346268.ch23.
Повний текст джерела
6
Tepper, Stewart J., and Deborah E. Tepper. "Treatment of Medication Overuse Headache." In The Cleveland Clinic Manual of Headache Therapy, 153–66. New York, NY: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0179-7_11.
Повний текст джерела
7
Tepper, Stewart J., and Deborah E. Tepper. "Treatment of Medication Overuse Headache." In The Cleveland Clinic Manual of Headache Therapy, 197–211. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-04072-1_13.
Повний текст джерела
8
Yalın, Osman Özgür, and Aynur Özge. "A Child with Medication Overuse Headache." In Headache in Children and Adolescents, 159–66. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28628-0_29.
Повний текст джерела
9
Negro, Andrea, and Paolo Martelletti. "Chronic Migraine Complicated by Medication Overuse Headache." In Case-Based Diagnosis and Management of Headache Disorders, 29–34. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06886-2_5.
Повний текст джерела
10
Cupini, Letizia M., Paola Sarchielli, and Paolo Calabresi. "Medication Overuse Headache: Causes, Consequences, and Treatment." In Drug Abuse and Addiction in Medical Illness, 351–62. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-3375-0_28.
Повний текст джерелаТези доповідей конференцій з теми "Medication overuse headache"
1
Brieva Herrero, MT, E. Marquez-Fernández, and N. Sánchez-Devicente. "4CPS-134 Prevalence analysis of patients treated with triptans at risk of developing medication overuse headache and development of a prescription optimisation strategy." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.235.
Повний текст джерела